I
IPS Academia Japan
IPS Academia Japan licenses the intellectual property that arises from IPS cell research
About IPS Academia Japan
IPS Academia Japan, Inc. operates as a pivotal technology licensing organization, specializing in induced pluripotent stem cell (iPS cell) technologies. Established on June 25, 2008, as an affiliate of Kyoto University, its primary mission is to manage and license the intellectual property stemming from iPS cell research to ensure these scientific advancements contribute to global health and welfare. The company's foundation is intrinsically linked to the groundbreaking research of Professor Shinya Yamanaka of Kyoto University, who was a co-recipient of the Nobel Prize in Physiology or Medicine in 2012 for the discovery that mature cells can be reprogrammed to become pluripotent.
The core of the company's business is to act as an intermediary between academia and industry. It manages a substantial patent portfolio, which includes the foundational patents from Professor Yamanaka's research, and licenses these technologies to a wide array of domestic and international entities. These clients range from pharmaceutical and biotech companies to manufacturers of research reagents and equipment. The business model is centered on granting non-exclusive licenses for the use of its extensive patent portfolio, which covers various aspects of iPS cell technology such as reprogramming, differentiation, purification, and culture methods. Revenue is generated through upfront fees, running royalties based on sales, and annual minimum royalties from its licensees.
Initially, the company's scope included research and cell sales, but it later transferred these activities to focus exclusively on patent licensing. This strategic shift allows it to concentrate on facilitating the widespread use of iPS cell technology in diverse applications, including drug discovery, disease modeling, toxicity screening, and the development of regenerative medicine. By making these patented technologies accessible, iPS Academia Japan plays a crucial role in accelerating research and development and the commercialization of new therapies and products. The organization is officially recognized as an Accredited Technology Licensing Organization (TLO) by Japan's Ministry of Education, Culture, Sports, Science and Technology (MEXT) and the Ministry of Economy, Trade and Industry (METI).
Source: Dealroom company dataNews
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VCOther financing | Feb 2015 | $11M | $43M | Undisclosed | — |
Growth signals
Latest recorded traffic for IPS Academia Japan is 2.3K monthly website visits, down 11.5% over the last three months. IPS Academia Japan's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
IPS Academia Japan in the Kyoto ecosystem
The IPS Academia Japan office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about IPS Academia Japan on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See IPS Academia Japan’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









